At a glance

ClinicalIndex Comparison Record

Phase 4Completed· 173 enrolled

Drug / intervention

Influenza Virus Vaccine, Fluzone® +1 morebiological

Likely dose

Influenza Virus Vaccine, Fluzone® 0.25 mLfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00390884

NCT00390884Phase 4Completed

Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation) Among Healthy Children Immunized in Fall 2005 With Fluzone Vaccine or Placebo

Sanofi Pasteur, a Sanofi Company·interventional·Posted Oct 23, 2006·Updated Apr 14, 2016

In Brief

A Phase 4 clinical trial evaluating Influenza Virus Vaccine, Fluzone® for Influenza. Completed, enrolled 173 participants across 5 sites.

To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsInfluenza

CountriesUnited States

Collaborators--

Phase 4CompletedFinished

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartOct 2006

First PostedOct 2006

Primary CompletionJun 2007

Study CompletionSep 2008

TodayJul 2026

First PostedOct 23, 2006

Enrollment StartOct 1, 2006

Primary CompletionJun 1, 2007

Study CompletionSep 1, 2008

TodayJul 2, 2026

Enrollment to primary: 8 monthsPosted 19.7 years ago

Influenza Virus Vaccine, Fluzone®biological

0.25 mL, Intramuscular

Influenza Virus Vaccine, Fluzone®biological

0.25 mL, Intramuscular